Use of JAK STAT Pathway Blocker To Treat COVID19 Patients - The Future of COVID19 Treatment

Corona Virus Disease 2019 (COVID19) is caused by SARS-COV2 which is a RNA type virus and spreads through droplets. COVID 19 is now a pandemic disease. In several researches it has been shown that this virus works through Angiotensin converting enzyme II (ACEII) and its receptor named ACEII receptor and ACE receptor 1 (AT1R). We are considering a new treatment pathway which is blocker of JAK-STAT pathway and STAT2 and STAT 6 pathway. ACE II receptors are expressed via JAK STAT pathway and STAT2, STAT3, STAT6 pathways. So with anti viral therapy, if we provide JAK-STAT pathway inhibitor like Baricitinib and Ruxolitinib then the treatment can show a better prognosis.